Caveolae compartmentalise β2-adrenoceptor signals by curtailing cAMP production and maintaining phosphatase activity in the sarcoplasmic reticulum of the adult ventricular myocyte

J Mol Cell Cardiol. 2012 Feb;52(2):388-400. doi: 10.1016/j.yjmcc.2011.06.014. Epub 2011 Jun 26.

Abstract

Inotropy and lusitropy in the ventricular myocyte can be efficiently induced by activation of β1-, but not β2-, adrenoceptors (ARs). Compartmentation of β2-AR-derived cAMP-dependent signalling underlies this functional discrepancy. Here we investigate the mechanism by which caveolae (specialised sarcolemmal invaginations rich in cholesterol and caveolin-3) contribute to compartmentation in the adult rat ventricular myocyte. Selective activation of β2-ARs (with zinterol/CGP20712A) produced little contractile response in control cells but pronounced inotropic and lusitropic responses in cells treated with the cholesterol-depleting agent methyl-β-cyclodextrin (MBCD). This was not linked to modulation of L-type Ca(2+) current, but instead to a discrete PKA-mediated phosphorylation of phospholamban at Ser(16). Application of a cell-permeable inhibitor of caveolin-3 scaffolding interactions mimicked the effect of MBCD on phosphorylated phospholamban (pPLB) during β2-AR stimulation, consistent with MBCD acting via caveolae. Biosensor experiments revealed β2-AR mobilisation of cAMP in PKA II signalling domains of intact cells only after MBCD treatment, providing a real-time demonstration of cAMP freed from caveolar constraint. Other proteins have roles in compartmentation, so the effects of phosphodiesterase (PDE), protein phosphatase (PP) and phosphoinositide-3-kinase (PI3K) inhibitors on pPLB and contraction were compared in control and MBCD treated cells. PP inhibition alone was conspicuous in showing robust de-compartmentation of β2-AR-derived signalling in control cells and a comparatively diminutive effect after cholesterol depletion. Collating all evidence, we promote the novel concept that caveolae limit β2-AR-cAMP signalling by providing a platform that not only attenuates production of cAMP but also prevents inhibitory modulation of PPs at the sarcoplasmic reticulum. This article is part of a Special Issue entitled "Local Signaling in Myocytes".

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium / metabolism
  • Caveolae / drug effects
  • Caveolae / metabolism*
  • Cells, Cultured
  • Chromones / pharmacology
  • Cyclic AMP / biosynthesis*
  • Heart Ventricles / drug effects
  • Heart Ventricles / metabolism
  • Male
  • Morpholines / pharmacology
  • Myocardial Contraction / drug effects
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphoric Monoester Hydrolases / metabolism*
  • Phosphorylation / drug effects
  • Protein Transport
  • Rats
  • Rats, Wistar
  • Receptors, Adrenergic, beta-2 / metabolism*
  • Sarcoplasmic Reticulum / enzymology*
  • Sarcoplasmic Reticulum / metabolism
  • Signal Transduction*
  • beta-Cyclodextrins / pharmacology

Substances

  • Chromones
  • Morpholines
  • Phosphoinositide-3 Kinase Inhibitors
  • Receptors, Adrenergic, beta-2
  • beta-Cyclodextrins
  • methyl-beta-cyclodextrin
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Cyclic AMP
  • Phosphoric Monoester Hydrolases
  • Calcium